Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.
Pharmacy benefit manager Express Scripts Holding Co. is talking with manufacturers about effectively lowering drug prices by introducing an identical product at a cheaper list price as an alternative to just reducing the list price of a brand already on the market.
The approach would be less disruptive to existing drug purchasing contracts with the supply chain and insurance plan financials and...
Create an account to read this article
Already a subscriber?
An appeal of a district court decision could help clarify patent law interaction with state price control efforts.
The big reimbursement reduction is based on a CMS survey of hospital purchases of 340B-discounted drugs and would represent a significantly deeper Medicare payment decrease than the first Trump Administration attempted.
Program designed to focus narrowly on obesity drug coverage but overlap with Part D could be complicated to navigate.
More collaboration on pricing and reimbursement across Europe could help the region respond to increased pressure to pay higher drug prices.
PharmaMar has described the joint clinical assessment process under the Health Technology Assessment Regulation as “demanding.”
Program designed to focus narrowly on obesity drug coverage but overlap with Part D could be complicated to navigate.
Could Novartis’ Itvisma or AstraZeneca’s Etcamah be the subject of the EU joint clinical assessment reports that follow Zepzelca and Imdylltra?
